

**The Board of Directors of Genovis AB (publ) resolves on fully underwritten rights issue and reschedules Annual General Meeting to May 5, 2015**

**The Board of Directors of Genovis AB (publ) has decided to reschedule the Annual General Meeting to May 5, 2015, as well as to raise capital through a fully underwritten rights issue, subject to approval by the AGM on May 5, 2015. The rights issue comprises a maximum of 14,563,768 shares and the subscription price will be SEK 1 per share. At full subscription the rights issue will raise approximately SEK 14.5 million before issue expenses for Genovis.**

Genovis is experiencing strong confidence in the company's products, with growing demand in both Europe and the US. The purpose of the rights issue is to be able to maintain the pace of sales and allow for a more powerful expansion in these two markets. Subscription and underwriting commitments have been obtained, corresponding to 100 percent of the total proceeds of the rights issue.

The Board proposes that the Annual General Meeting approve the Board's proposal to conduct a preferential rights issue of shares in which three (3) existing shares entitle the holder to subscription for two (2) new shares at a subscription price of SEK 1/ share. As a result of this resolution share capital could increase by a maximum of SEK 3,640,942 through the issuance of up to 14,563,768 shares. In the event that all shares are not subscribed for on the basis of subscription rights, allocation of shares shall be made within the scope of the maximum amount of the share issue, at which the Board shall allocate the shares firstly to those who have subscribed for shares on basis of subscription rights, pro rata in relation to their subscription on the basis of subscription rights, secondly to those who have declared their interest to subscribe for shares without subscription rights, pro rata in relation to their declared interest and last to guarantors in proportion to their guarantee undertakings.

Following the completed rights issue, share capital will amount to a maximum of SEK 9,102,355 and the number of shares to a maximum of 36,409,420. The company will raise about SEK 14.5 million before issue expenses, which are expected to be about SEK 500,000. The issue will have a dilutive effect of 40 percent on the holdings of those who do not subscribe to the rights issue for their full stake.

**Timetable for rights issue**

May 11, 2015	Last trading day for the Genovis share including subscription rights for the new issue.
May 13, 2015	Record date for participation in the new issue; shareholders registered in Genovis' share register on this day receive subscription rights for participation in the new issue.
May 18 – June 1, 2015	Subscription period. Subscription with preferential rights through cash payment during the subscription period. Shareholders may report their intention to subscribe throughout the subscription period.



Resolutions on the issuance of shares are subject to and conditional upon the Meeting also resolving on reduction of share capital and amendment of the Articles of Association; both of these resolutions are proposed to the same General Meeting.

A Memorandum will be sent to the company's shareholders that will provide the full terms, instructions and more information on the rights issue and Genovis. The Memorandum will be available on the company's website [www.genovis.com](http://www.genovis.com) beginning on May 13, 2015.

The notice is published in a separate press release and will be published in Post- och Inrikes tidningar and on the company's website within the next few days.

For more information please contact the CEO of Genovis AB (publ), Sarah Fredriksson, tel +46 (0)46-10 12 35 or e-mail [sarah.fredriksson@genovis.com](mailto:sarah.fredriksson@genovis.com)

#### **ABOUT GENOVIS**

Genovis' business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes in innovative product formats that facilitate development and quality control of biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

*Genovis shares are listed on Nasdaq Stockholm First North and Consensus is our certified advisor.  
T +46 (0)31-745 50 00*

*This document is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.*